Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Hamburg - Delayed Quote EUR

Certara, Inc. (700.HM)

11.26
-0.16
(-1.40%)
As of 5:25:18 PM GMT+2. Market Open.
Loading Chart for 700.HM
  • Previous Close 11.41
  • Open 11.62
  • Bid 11.28 x --
  • Ask 11.52 x --
  • Day's Range 11.26 - 11.62
  • 52 Week Range 7.85 - 16.11
  • Volume 126
  • Avg. Volume 0
  • Market Cap (intraday) 1.831B
  • Beta (5Y Monthly) 1.57
  • PE Ratio (TTM) --
  • EPS (TTM) -0.07
  • Earnings Date May 5, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

www.certara.com

1,487

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 700.HM

View More

Performance Overview: 700.HM

Trailing total returns as of 5/5/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

700.HM
12.33%
S&P 500 (^GSPC)
3.44%

1-Year Return

700.HM
30.42%
S&P 500 (^GSPC)
10.76%

3-Year Return

700.HM
37.82%
S&P 500 (^GSPC)
36.96%

5-Year Return

700.HM
50.64%
S&P 500 (^GSPC)
98.00%

Compare To: 700.HM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 700.HM

View More

Valuation Measures

Annual
As of 5/2/2025
  • Market Cap

    1.85B

  • Enterprise Value

    1.97B

  • Trailing P/E

    --

  • Forward P/E

    28.49

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.38

  • Price/Book (mrq)

    1.97

  • Enterprise Value/Revenue

    5.79

  • Enterprise Value/EBITDA

    30.82

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -3.13%

  • Return on Assets (ttm)

    0.75%

  • Return on Equity (ttm)

    -1.15%

  • Revenue (ttm)

    385.15M

  • Net Income Avi to Common (ttm)

    -12.05M

  • Diluted EPS (ttm)

    -0.07

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    181.4M

  • Total Debt/Equity (mrq)

    29.46%

  • Levered Free Cash Flow (ttm)

    67.68M

Research Analysis: 700.HM

View More

Company Insights: 700.HM

Research Reports: 700.HM

View More

People Also Watch